The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Chelating Activity of Advanced Glycation End-product Inhibitors
Open accessAbstract
The advanced glycation end-product (AGE) hypothesis proposes that accelerated chemical modification of proteins by glucose during hyperglycemia contributes to the pathogenesis of diabetic complications. The two most commonly measured AGEs, N(epsilon)-(carboxymethyl)lysine and pentosidine, are glycoxidation products, formed from glucose by sequential glycation and autoxidation reactions. Although several compounds have been developed as AGE inhibitors and are being tested in animal models of diabetes and in clinical trials, the mechanism of action of these inhibitors is poorly understood. In general, they are thought to function as nucleophilic traps for reactive carbonyl intermediates in the formation of AGEs; however alternative mechanisms of actions, such as chelation, have not been rigorously examined. To distinguish between the carbonyl trapping and antioxidant activity of AGE inhibitors, we have measured the chelating activity of the inhibitors by determining the concentration required for 50% inhibition of the rate of copper-catalyzed autoxidation of ascorbic acid in phosphate buffer. All AGE inhibitors studied were chelators of copper, as measured by inhibition of metal-catalyzed autoxidation of ascorbate. Apparent binding constants for copper ranged from approximately 2 mm for aminoguanidine and pyridoxamine, to 10-100 microm for carnosine, phenazinediamine, OPB-9195 and tenilsetam. The AGE-breakers, phenacylthiazolium and phenacyldimethylthiazolium bromide, and their hydrolysis products, were among the most potent inhibitors of ascorbate oxidation. We conclude that, at millimolar concentrations of AGE inhibitors used in many in vitro studies, inhibition of AGE formation results primarily from the chelating or antioxidant activity of the AGE inhibitors, rather than their carbonyl trapping activity. Further, at therapeutic concentrations, the chelating activity of AGE inhibitors and AGE-breakers may contribute to their inhibition of AGE formation and protection against development of diabetic complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441
Self-citationAminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking
Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., & Cerami, A. (1986) · Science · doi:10.1126/science.3487117 · Cited by 1,146
Protein glycation and oxidative stress in diabetes mellitus and ageing
Wolff, S. P., Jiang, Z. Y., & Hunt, J. V. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90040-a · Cited by 883
Glomb, M. A., & Monnier, V. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.17.10017 · Cited by 576
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
Vasan, S., Zhang, X., Zhang, X., Kapurniotu, A., Bernhagen, J., Teichberg, S., Basgen, J., Wagle, D., Shih, D., Terlecky, I., et al. (1996) · Nature · doi:10.1038/382275a0 · Cited by 466
Fu, M.-X., Wells-Knecht, K. J., Blackledge, J. A., Lyons, T. J., Thorpe, S. R., & Baynes, J. W. (1994) · Diabetes · doi:10.2337/diab.43.5.676 · Cited by 464
Self-citationBreakers of advanced glycation end products restore large artery properties in experimental diabetes
Wolffenbuttel, B. H. R., Boulanger, C. M., Crijns, F. R. L., Huijberts, M. S. P., Poitevin, P., Swennen, G. N. M., Vasan, S., Egan, J. J., Ulrich, P., Cerami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4630 · Cited by 434
Carnosine: Its properties, functions and potential therapeutic applications
Quinn, P. J., Boldyrev, A. A., & Formazuyk, V. E. (1992) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(92)90006-l · Cited by 306
In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs)
Booth, A. A., Khalifah, R. G., Todd, P., & Hudson, B. G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5430 · Cited by 286
Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging
Thorpe, S. R., & Baynes, J. W. (1996) · Drugs & Aging · doi:10.2165/00002512-199609020-00001 · Cited by 285
Self-citationAmadorins: Novel Post-Amadori Inhibitors of Advanced Glycation Reactions
Khalifah, R. G., Baynes, J. W., & Hudson, B. G. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0371 · Cited by 268
Self-citationOnorato, J. M., Jenkins, A. J., Thorpe, S. R., & Baynes, J. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003263200 · Cited by 250
Self-citationNakamura, S., Makita, Z., Ishikawa, S., Yasumura, K., Fujii, W., Yanagisawa, K., Kawata, T., & Koike, T. (1997) · Diabetes · doi:10.2337/diab.46.5.895 · Cited by 235
THORNALLEY, P., WOLFF, S., CRABBE, J., & STERN, A. (1984) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(84)90131-4 · Cited by 217
Thornalley, P. J., Yurek-George, A., & Argirov, O. K. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00287-2 · Cited by 214
Biological effects of aminoguanidine: An update
Nilsson, B.-O. (1999) · Inflammation Research · doi:10.1007/s000110050495 · Cited by 212
Dunn, J. A., Ahmed, M. U., Murtiashaw, M. H., Richardson, J. M., Walla, M. D., Thorpe, S. R., & Baynes, J. W. (1990) · Biochemistry · doi:10.1021/bi00501a014 · Cited by 170
Self-citationMiyata, T., Fu, M.-X., Kurokawa, K., de Strihou, C. V. Y., Thorpe, S. R., & Baynes, J. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00093.x · Cited by 161
Self-citationBaran, E. J. (2000) · PubMed · Cited by 135
Glucose Modification of Human Serum Albumin: A Structural Study
Coussons, P. J., Jacoby, J., McKay, A., Kelly, S. M., Price, N. C., & Hunt, J. V. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00557-6 · Cited by 104
Novel Inhibitors of Advanced Glycation Endproducts (Part II)
Rahbar, S., Yerneni, K. K. V., Scott, S., Gonzales, N., & Lalezari, I. (2000) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.2000.0239 · Cited by 101
Miyata, T., Ueda, Y., Asahi, K., Izuhara, Y., Inagi, R., Saitō, A., de Strihou, C. V. Y., & Kurokawa, K. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1191719 · Cited by 90
Chace, K. V., Carubelli, R., & Nordquist, R. E. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90223-6 · Cited by 87
Hawkins, C. L., & Davies, M. J. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(96)00069-5 · Cited by 86
Münch, G. W., Taneli, Y., Schraven, E., Schindler, U., Schinzel, R., Palm, D., & Riederer, P. F. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260940 · Cited by 69
Diabetes in the New Millennium
Turtle, J. R., Kaneko, T., & Osato, S. (1999) · Medical Entomology and Zoology · Cited by 68
Thornalley, P. J., & Minhas, H. S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00284-6 · Cited by 68
[8] Use of ascorbate as test for catalytic metals in simple buffers
Buettner, G. R. (1990) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(90)86100-a · Cited by 65
Human type 2 diabetes: morphological evidence for abnormal beta-cell function.
Sempoux, C. L., Guiot, Y., Dubois, D., Moulin, P., & Rahier, J. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s172 · Cited by 64
Inhibitory Effects of Tenilsetam on the Maillard Reaction
Shoda, H., Miyata, S., Liu, B.-F., Yamada, H., Ohara, T., Suzuki, K., Oimomi, M., & Kasuga, M. (1997) · Endocrinology · doi:10.1210/endo.138.5.5151 · Cited by 61
Effects of an extracellular metal chelator on neurovascular function in diabetic rats
Cameron, N. E., & Cotter, M. A. (2001) · Diabetologia · doi:10.1007/s001250051669 · Cited by 54
Novel Inhibitors of Advanced Glycation Endproducts
Rahbar, S., Yerneni, K. K. V., Scott, S., Gonzales, N., & Lalezari, I. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1275 · Cited by 54
Antioxidant characteristics of some potential anticataract agents
Woollard, A. C. S., Wolff, S. P., & Bascal, Z. A. (1990) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(90)90004-3 · Cited by 46
Soulis, T., Sastra, S. A., Thallas, V., Mortensen, S. B., Wilken, M., Clausen, J. T., Bjerrum, O. J., Petersen, H., Lau, J. F., Jerums, G., et al. (1999) · Diabetologia · doi:10.1007/s001250051181 · Cited by 46
Lee, K., Simpson, G., & ORTWERTH, B. J. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00097-0 · Cited by 43
Glycochelates and the etiology of diabetic peripheral neuropathy
Qian, M., & Eaton, J. W. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00262-2 · Cited by 42
Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats
Keegan, A., Cotter, M. A., & Cameron, N. E. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00125-2 · Cited by 37
Litchfield, J., Thorpe, S. R., & Baynes, J. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00091-6 · Cited by 36
Self-citationStabilities of metal chelates of pyridoxamine
Gustafson, R. L., & Martell, A. E. (1957) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(57)90379-x · Cited by 30
Jiang, Z. Y., Qiong-Lin, Z., Eaton, J. W., Koppenol, W. H., Hunt, J. V., & Wolff, S. P. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90265-7 · Cited by 20
Detoxification of Methylglyoxal by the Nucleophilic Bidentate, Phenylacylthiazolium Bromide
Ferguson, G. P., VanPatten, S., Bucala, R., & Al‐Abed, Y. (1999) · Chemical Research in Toxicology · doi:10.1021/tx990007y · Cited by 15
Cited by
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150
“Due to the involvement of oxidants and metals, such as iron and cooper in the formation of AGEs, the search for antioxidative and chelating nutrients is of increasing interest [42].”
BackgroundCopper, oxidative stress, and human health
Uriu-Adams, J. Y., & Keen, C. L. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.07.015 · Cited by 975
Diabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts
Thornalley, P. J. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.013 · Cited by 682
Negre‐Salvayre, A., Coatrieux, C., Ingueneau, C., & Salvayre, R. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707395 · Cited by 641
Metadata
- Authors
- Price, D. L., Rhett, P. M., Thorpe, S. R., & Baynes, J. W.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 276
- Issue
- 52
- Pages
- 48967-48972
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2082865005
- Cited by
- 308
- References
- 41
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.